Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression

European Journal of Haematology

Volumn 77, Issue 4, 2006, Pages 309-317

  Matthews, Christine ^a,b   Catherwood, Mark A ^a   Morris, T C M ^a   Kettle, Paul J ^a   Drake, Mary B ^a   Gilmore, William S ^b   Alexander, H Denis ^a,b  

^a BELFAST CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Chronic lymphocytic leukaemia; Gene usage; IgVH mutational status; Thymidine kinase

Indexed keywords

CD38 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; PROTEIN KINASE ZAP 70; RITUXIMAB; THYMIDINE KINASE;

ADULT; AGED; ARTICLE; CANCER STAGING; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; ENZYME BLOOD LEVEL; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD38; CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYMIDINE KINASE;

EID: 33748354035     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2006.00707.x     Document Type: Article

References (52)

1. ROZMAN C, MONTSERRAT E. Chronic lymphocytic leukaemia. N Engl J Med 1995;333:1052-1057.
2. DAMLE RN, WASIL T, FAIS F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847.
3. HAMBLIN TJ, DAVIS Z, GARDINER A, OSCIER DG, STEVENSON FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1854.
4. DÖHNER H, STILGENBAUER S, DÖHNER K, BENTZ M, LICHTER P. Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. J Mol Med 1999;77:266-281.
5. DÖHNER H, STILGENBAUER S, BENNER A, LEUPOLT E, KRÖBER A, BULLINGER L, DÖHNER K, BENTZ M, LICHTER P. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916.
6. KRÖBER A, SEILER T, BENNER A, BULLINGER L, BRUCKLE E, LICHTER P, DÖHNER H, STILGENBAUER S. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100:1410-1416.
7. HAMBLIN TJ, ORCHARD JA, IBBOTSON RE, DAVIS Z, THOMAS PW, STEVENSON FK, OSCIER DG. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002;99:1023-1029.
8. OSCIER DG, GARDINER AC, MOULD SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002;100:1177-1184.
9. WIESTNER A, ROSENWALD A, BARRY TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:4944-4951.
10. CRESPO M, BOSCH F, VILLAMOR N, BELLOSILLO B, COLOMER D, ROZMAN M, MARCE S, LOPEZ-GUILLERMO A, CAMPO E, MONTSERRAT E. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-1775.
11. ORCHARD JA, IBBOTSON RE, DAVIS Z, WIESTNER A, ROSENWALD A, THOMAS PW, HAMBLIN TJ, STAUDT LM, OSCIER DG. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363:105-111.
12. RASSENTI LZ, HUYNH L, TOY TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893-901.
13. STILGENBAUER S, BULLINGER L, LICHTER P, DÖHNER H. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukaemia 2002;16:993-1007.
14. PETTITT AR, SHERRINGTON PD, STEWART G, CAWLEY JC, TAYLOR AMR, STANKOVIC T. p53 dysfunction in B-cell chronic lymphocytic leukaemia: inactivation of ATM as an alternative to TP53 mutation. Blood 2001;98:814-822.
15. STURM I, BOSANQUET AG, HERMANN S, GUNER D, DORKEN B, DANIEL PT. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death and Differentiation 2003;10:477-484.
16. HAMBLIN TJ, ORCHARD JA, GARDINER A, OSCIER DG, DAVIS Z, STEVENSON FK. Immunoglobulin V genes and CD38 expression in CLL. Blood 2000;95:2455-2456.
17. THUNBERG U, JOHNSON A, ROOS G, THORN I, TOBIN G, SALLSTROM J, SUNDSTROM C, ROSENQUIST R. CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. Blood 2001;97:1892-1893.
18. ROSENWALD A, ALIZADEH AA, WIDHOPF G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1625-1638.
19. OPPEZZO P, VASCONCELOS Y, SETTEGRANA C, et al. French Cooperative Group on CLL. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood 2005;106:650-657.
20. RICHARDSON SJ, MATTHEWS C, CATHERWOOD MA, et al. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B cell chronic lymphocytic leukaemia (B-CLL). Blood 2006;107:3584-3592.
21. TOBIN G, THUNBERG U, LAURELL A, et al. Patients with chronic lymphocytic leukemia with mutated VH genes presenting with Binet stage B or C form a subgroup with a poor outcome. Haematologica 2005;90:465-469.
22. KEATING MJ, LERNER S, KANTARJIAN H, FREIRECH EJ, O'BRIEN S. The serum β2 microglobulin (β2M) level is more powerful than stage in predicting response and survival in chronic lymphocytic leukaemia (CLL). Blood 1998;86:606a [Abstract 412].
23. SARFATI M, CHEVRET S, CHASTANG C, BIRON G, STRYCKMANS P, DELESPESSE G, BINET JL, MERLE-BERAL H, BRON D. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood 1996;88:4259-4264.
24. HALLEK M, WANDERS L, STROHMEYER S, EMMERICH B. Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications. Ann Hematol 1992;65:1-5.
25. HANNIGAN BM, BARNETT YA, ARMSTRONG DB, MCKELVEY-MARTIN VJ, MCKENNA PG. Thymidine kinases: the enzymes and their clinical usefulness. Cancer Biother 1993;8:189-197.
26. WINTERSBERGER E, ROTHEBEDER H, SEISER C. Regulation of thymidine kinase during growth, cell cycle and differentiation. Adv Enzyme Regul (1992) 1992; 241-254.
27. JOHANSSON M, BRISMAR S, KARLSSON A. Human deoxycytidine kinase is located in the cell nucleus. Proc Natl Acad Sci USA 1997;94, 11941-11945.
28. ELLIMS PH, GAN TE, MEDLEY G, VAN DER WEYDEN MB. Prognostic relevance of thymidine kinase isozymes in adult non-Hodgkin's lymphoma. Blood 1981;58:926-930.
29. ELLIMS, P.H., GAN, T.E., VAN DER WEYDEN, M.B. Thymidine kinase isoenzymes in chronic lymphocytic leukaemia. Br J Haematol 1981;49:479-481.
30. GRONOWITZ JS, HAGBERG H, KALLANDER CF, SIMONSSON B. The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma. Br J Cancer 1983;47:487-495.
31. GRONOWITZ JS, KALLANDER FR, DIDERHOLM H, HAGBERG H, PETTERSSON U. Application of an in vitro assay for serum thymidine kinase: results on viral disease and malignancies in humans. Int J Cancer 1984;33:5-12.
32. MAGNAC C, PORCHER R, DAVI F, NATAF J, PAYELLE-BROGARD B, TANG RP, OPPEZZO P, LEVY V, DIGHIERO G, AJCHENBAUM-CYMBALISTA F. Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL. Leukemia 2003;17:133-137.
33. SIMONSSON B, KALLANDER CF, BRENNING G, KILLANDER A, AHRE A, GRONOWITZ JS. Evaluation of serum deoxythymidine kinase as a marker in multiple myeloma. Br J Haematol 1985;61:215-224.
34. HALLEK M, WANDERS L, OSTWALD M, BUSCH R, SENEKOWITSCH R, STERN S, SCHICK HD, KUHN-HALLEK I, EMMERICH B. Serum beta (2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 1996;22:439-447.
35. HALLEK M, LANGENMAYER I, NERL C, et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 1999;93:1732-1737.
36. van DONGEN JJM, LANGERAK AW, BRUGGEMANN M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH$-CT98-3936. Leukemia 2003;17:2257-2317.
37. MATTHEWS C, CATHERWOOD MA, MORRIS TCM, ALEXANDER H.D. Routine analysis of IgVH mutational status in CLL patients using BIOMED-2 standardized primers and protocols. Leuk Lymphoma 2004;45:1899-1904.
38. ALEXANDER HD, CATHERWOOD MA, BEATTIE RGG, CUTHBERT RJG, KETTLE PJ, MARKEY GM, MORRIS TCM. Immunophenotyping in the differential diagnosis of mantle cell lymphoma/leukaemia. Leuk Lymphoma 2001;42:41.
39. CATHERWOOD MA, MATTHEWS C, NIBLOCK R, DOBBIN E, MORRIS TCM, ALEXANDER HD. Zap-70 mRNA quantification in B-cell chronic lymphocytic leukaemia. Eur J Hematol 2006;76:294-298.
40. DI RAIMONDO F, GIUSTOLISI R, LERNER S, CACCIOLA E, O'BRIEN S, KANTARJIAN H, KEATING MJ. Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. Ann Oncol 2001;12:621-625.
41. GARDINER AC, DAVIS ZA, GLIDE S, MOULD SJ, OSCIER DG. Prognostic significance of trisomy 12 in CLL. Leuk Lymphoma 2005;46:S55.
42. KIENLE DL, KORZ C, HOSCH B, et al. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes. J Clin Oncol 2005;23:3780-3792.
43. JOHNSON DG, SCHWARZ JK, CRESS WD, NEVINS JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 1993;365:349-352.
44. SHIN EK, TEVOSIAN SG, YEE AS. The N-terminal region of E2F-1 is required for the transcriptional activation of a new class of target promoter. J Biol Chem 1996;271:12261-12268.
45. NOLLET F, CAUWELIER B, BILLIET J, SELLESLAG D, VAN HOOF A, LOUWAGIE A, CRIEL A. Do B-cell chronic lymphocytic leukemia patients with Ig VH3-21 genes constitute a new subset of chronic lymphocytic leukemia? Blood 2002;100:1097-1098.
46. TOBIN G, THUNBERG U, JOHNSON A, et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 2003;101:4952-4957.
47. TOBIN G, SODERBERG O, THUNBERG U, ROSENQUIST R. V(H)3-21 gene usage in chronic lymphocytic leukemia-characterization of a new subgroup with distinct molecular features and poor survival. Leuk Lymphoma 2004;45:221-228.
48. TOBIN G, ROSENQUIST R. Prognostic usage of V(H) gene mutation status and its surrogate markers and the role of antigen selection in chronic lymphocytic leukemia. Med Oncol 2005;22:217-228.
49. LIN K, MANOCHA S, HARRIS RJ, MATRAI Z, SHERRINGTON PD, PETTITT AR. High frequency of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia patients using the VH3-21 gene segment. Blood 2003;103:1145-1146.
50. GHIA P, STAMATOPOULOS K, BELESSI C, et al. Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood 2005;105:1678-1685.
51. THORSELIUS M, KROBER A, MURRAY F, et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-utilizing chronic lymphocytic leukemia independent of geographical origin and mutational status. Blood 2006;107:2889-2894.
52. FALT S, MERUP M, TOBIN G, THUNBERG U, GAHRTON G, ROSENQUIST R, WENNBORG A. Distinctive gene expression pattern in VH3-21 utilizing B-cell chronic lymphocytic leukemia. Blood 2005;106:681-689.